A Phase 3 interventional study of Placebo and PF-04965842 in Atopic Dermatitis, sponsored by Pfizer. Completed at 136 sites in 14 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-04-13.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is one of 10 in phase 3, and was the 8th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer
Ages 2–5
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 287 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 150 across the 20 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
58 studies in Dermatitis, Atopic by Pfizer: 11 open now, 13 under way, 4 of them phase 3. Of 43 finished, 34 (79%) have results posted.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 16th largest by enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2019, is one of 17 in phase 3, and was the 20th registered.
Pfizer’s Dermatitis, Atopic studies by the year they started, since 2009.
1 of the studies testing abrocitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07848074Fondazione Policlinico Universitario Agostino Gemelli IRCCSAbrocitinib Dose Tapering in Patients With Atopic Dermatitis | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, from their registry updates:
Among Pfizer’s 58 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to \<18 years of age with moderate to severe AD.
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to \<18 years of age with moderate to severe AD. Participants will be screened within 28 days prior to the first dose of study intervention to confirm study eligibility. Subjects must have moderate-severe AD involving at least 10% Body Surface Area (BSA); an Investigator Global Assessment (IGA) score of at least 3; an Eczema Area Severity Index (EASI) of at least 16 and Peak Pruritus Numerical Rating Score (NRS) of at least 4 on baseline/Day 1. Eligible subjects will be randomized at the Baseline/Day 1 visit. Approximately 225 participants will be randomized in a 1:1:1 ratio to receive once daily PF 04965842 at 200 mg, 100 mg, or placebo for 12 weeks. Randomization will be stratified by baseline disease severity (moderate [IGA = 3] vs. severe [IGA = 4] AD). The investigational products will be administered QD for 12 weeks. Background therapy (medicated and non-medicated topical therapy) must be applied BID for the duration of the treatment period. The co-primary efficacy endpoints are an IGA score of clear (0) or almost clear (1) with a reduction from baseline of greater than 2 points at Week 12 AND an at least 75% improvement of the EASI score (EASI-75) at week 12. Safety and efficacy assessments will be conducted at the investigator site by a clinical assessor blinded to treatment assignment. Scheduled clinic or telephone study visits for all subjects will occur at Screening, Baseline/Day 1, Day 8 (by phone), Day 15, Day 29, Day 43 (by phone), Day 57, Day 85 (End of treatment/Early termination), Day 113 (End of Study). Participants discontinuing early from the study will undergo a 4 week follow up period.
This study includes an immunogenicity sub study integrated into the last 4 weeks of the main study treatment period. At Week 8, up to approximately 90 participants (up to approximately 30 in each treatment arm) who have completed 8 weeks of treatment with study intervention will receive a tetanus, diphtheria and acellular pertussis combination vaccine (Tdap), and collection of blood samples for the evaluation of immunogenicity at Weeks 8 and 12. Participants of this sub study will complete all other protocol specified procedures in the main study.
At the end of the 12 week study treatment, qualified participants completing the study will have the option to enter the long term extension (LTE) study B7451015.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
active
Drug: PF-04965842
active
Drug: PF04965842
Placebo
100 mg QD
200 mg QD
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and ≥2 Points Improvement From Baseline at Week 12
The IGA of Atopic Dermatitis (AD) was scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline to Week 12
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline at Week 12
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline to Week 12
Percentage of Participants Achieving ≥4 Points Improvement From Baseline in Peak Pruritis Numeric Rating Scale (PP-NRS) for Severity of Pruritus at Weeks 2, 4 and 12
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Weeks 2, 4 and 12
Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) at Week 12
The PSAAD is a daily patient reported symptom diary presented as a 15 item questionnaire that includes 11 items developed to measure symptoms of AD, along with 4 additional items for exploratory and psychometric validation purposes (Sleep \& Usual Activities Questions and Patient Global Impression of Severity \& Patient Global Impression of Change Questions). Participants answer each question about skin condition based on a 24 hour recall. Each question was evaluated on a 11-point scale ranging from 0 to 10, where higher scores indicate more impact on skin condition.The PSAAD total score is calculated as the average of the responses to each of the 11 items and ranges from 0 (none) to 10 (extreme), where higher scores indicate worse severity of AD symptoms.
Time frame: Baseline to Week 12
Percentage of Participants Achieving IGA Response of 'Clear' or 'Almost Clear' and ≥2 Points Improvement From Baseline at All Scheduled Time Points Except Week 12
The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Weeks 2, 4 and 8
Percentage of Participants Achieving EASI Response ≥ 75% Improvement From Baseline at All Scheduled Time Points Except Week 12
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Weeks 2, 4 and 8
Percentage of Participants Achieving EASI Response ≥ 50% Improvement From Baseline
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percentage of Participants Achieving EASI Response ≥ 90% Improvement From Baseline
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percentage of Participants Achieving EASI Response =100% Improvement From Baseline
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percent Change From Baseline in EASI Score
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percentage of Participants Achieving ≥4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus at All Scheduled Time Points Other Than Weeks 2, 4 and 12
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Time to First Achieve ≥4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10).
Time frame: Baseline to Week 16
Percent Change From Baseline in PP-NRS for Severity of Pruritus
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10).
Time frame: Baseline, Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
Change From Baseline in Percentage Body Surface Area (BSA)
BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percent Change From Baseline in Percentage BSA
BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percentage of Participants Achieving Percentage BSA < 5% at Week 12
BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.
Time frame: Baseline to Week 12
Percentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response ≥ 50% Improvement From Baseline
SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percentage of Participants Achieving SCORAD Response ≥ 75% Improvement From Baseline
SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Change From Baseline in SCORAD Total Score
SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percent Change From Baseline in SCORAD Total Score
SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Change From Baseline in SCORAD Subjective Visual Analogue Scale (VAS) of Sleep Loss
SCORAD is a validated scoring index for AD, which combines extent (A, 0-100), severity (B, 0-18), and subjective symptoms (C, 0-20) based on pruritus and sleep loss, each scored (0-10). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (ie, itch and sleep loss) are each scored by the participant using a VAS where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleep loss). The value for each should reflect the average on a 10 point scale for the last 3 days/nights. Changes from baseline in SCORAD subjective assessments of itch were not evaluated. Only changes from baseline in SCORAD subjective assessments of sleep loss are presented below.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percent Change From Baseline in SCORAD Subjective VAS of Sleep Loss
SCORAD is a validated scoring index for AD, which combines extent (A, 0-100), severity (B, 0-18), and subjective symptoms (C, 0-20) based on pruritus and sleep loss, each scored (0-10). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (ie, itch and sleep loss) are each scored by the participant using a VAS where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleep loss). The value for each should reflect the average on a 10 point scale for the last 3 days/nights. Changes from baseline in SCORAD subjective assessments of itch were not evaluated. Only changes from baseline in SCORAD subjective assessments of sleep loss are presented below.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Number of Days When a Corticosteroid Not Used up to Day 88
Time frame: Baseline to Day 88
Change From Baseline in Children's Dermatology Life Quality Index (DLQI)
The DLQI is a general dermatology questionnaire that consists of 10 items to assess participant-reported health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment).The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 3-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percentage of Participants With ≥2.5 Points at Baseline and Achieving ≥2.5 Points Improvement From Baseline in Children's DLQI
The DLQI is a general dermatology questionnaire that consists of 10 items to assess participant-reported health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment).The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 3-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality. Participants who withdrew from the study were counted as non-responder.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Change From Baseline in Anxiety of Hospital Anxiety and Depression Scale (HADS)
The HADS is a 14-item patient reported outcome (PRO) measure used to detect states of anxiety and depression over the past week. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Change From Baseline in Depression of HADS
The HADS is a 14-item patient reported outcome (PRO) measure used to detect states of anxiety and depression over the past week. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Change From Baseline in Patient-Oriented Eczema Measure (POEM)
The POEM is a 7-item PRO measure used to assess the impact of AD over the past week. Each item is scored as "no days (0)", "1-2 days (1)", "3-4 days (2)", "5-6 days (3)" and "every day (4)". The score ranges from 0 to 28. The higher values represent more severe AD.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Change From Baseline in Dermatitis Family Impact (DFI) at Week 12
The DFI is a validated 10-item measure filled out by the parent/caregiver of the patient used to assess the impact of the patient's eczema on the family. The instrument has a recall period of 7 days. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" or "not at all (0)". The score can range from 0 to 30. The higher values represent the worse impact.
Time frame: Baseline to Week 12
Change From Baseline in Patient Global Assessment (PtGA)
The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the IGA were used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percentage of Participants With ≥2 Points at Baseline and Achieving 'Clear' or 'Almost Clear' and ≥2 Points Improvement From Baseline in PtGA
The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the IGA were used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Change From Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y) VAS Score
The EQ-5D is a validated, standardized, generic instrument that is the most widely used preference based health related quality of life questionnaire in cost effectiveness and health technologies assessment. The EQ-5D-Y is a version of the instrument specifically developed and validated for use by youths aged 12 through 17 years. Components assess level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. Score scale for each domain ranges from 1 (minimum) to 3 (maximum), with higher scores indicating worse health condition. In addition, respondents use a vertical, graduated Visual Analogue Scale (VAS) to rate their own health between 0 (the worst) and 100 (the best health state he/she can imagine).
Time frame: Baseline, Weeks 2, 4, 8 and 12
Change From Baseline in Pediatric Functional Assessment of Chronic Illness Therapy Fatigue Scale (Peds-FACIT-F) at Week 12
The Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F) is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (none of the time) to 4 (all of the time). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score), with higher scores representing better overall health status (less fatigue). Changes from baseline at Week 12 are presented below. Changes from baseline at other scheduled time points were not evaluated.
Time frame: Baseline to Week 12
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.
Time frame: 16 weeks
Number of Participants With Serious Adverse Events (SAEs)
A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.
Time frame: 16 weeks
Number of Participants Who Discontinued From the Study Due to TEAEs
An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.
Time frame: 16 weeks
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
Laboratory tests included hematology (including coagulation panel), clinical chemistry, lipid profile panel, and routine urinalysis. LLN is lower limit of normal. ULN is upper limit of normal.
Time frame: 16 weeks
Number of Participants With Electrocardiogram (ECG) Data Meeting Prespecified Criteria
A 12-lead ECG was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT intervals. All scheduled ECGs were performed after the participant had rested quietly for at least 10 minutes in a supine position. Reading of ECGs were performed by a central reader who has expertise reading and interpreting ECGs in adolescents. The QTcF interval is the only prespecified ECG criteria (Marked prolongation of the QTcF interval to \>500 ms or \>60 ms change from screening ECG); data are presented below.
Time frame: 16 weeks
Categorization of Vital Signs Data Meeting Prespecified Criteria
Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the seated position, after having sat calmly for at least 5 minutes.
Time frame: 16 weeks
Fold Increase of Immunoglobulin G (IgG) Concentrations Against Specific Vaccine Antigens at 4 Weeks Post-Vaccination
The immunogenicity analysis was to evaluate the effect of abrocitinib on immunogenicity to a tetanus, diphtheria and pertussis combination vaccine (Tdap) vaccine in adolescent participants 12 to \<18 years of age with moderate to severe AD. Participants who completed 8 weeks of treatment with study intervention received Tdap at Week 8, and had blood samples collected for the evaluation of immunogenicity to the vaccine at Weeks 8 and 12. The fold increase was defined as the ratio (post-vaccination: pre-vaccination) of concentration values. The geometric mean fold rise (GMFR) is presented below, and was calculated by first arithmetically averaging the logarithmically transformed ratio (post-vaccination: pre-vaccination) values, and then back transformation. A 95% CI for GMFR was constructed by back transformation of the CI for the logarithmically transformed GMFRs computed using the Student's t distribution.
Time frame: 4 weeks post-vaccination with Tdap (Week 12)
Plasma PF-04965842 Concentration at Week 8
Time frame: 2 hours pre-dose at Week 8
Plasma PF-04965842 Concentration at Week 12
Time frame: 2 hours post-dose at Week 12
| Milestone | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Started | 96 | 95 | 94 |
| Completed | 90 | 92 | 91 |
| Not completed | 6 | 3 | 3 |
| Withdrew: Adverse event | 2 | 1 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Participant did not complete week 16 due to covid-19 impact | 1 | 0 | 0 |
The IGA of Atopic Dermatitis (AD) was scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and ≥2 Points Improvement From Baseline at Week 12 | 24.5 (15.8 to 33.2) | 41.6 (31.3 to 51.8) | 46.2 (36.1 to 56.4) |
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline at Week 12 | 41.5 (31.5 to 51.4) | 68.5 (58.9 to 78.2) | 72.0 (62.9 to 81.2) |
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 12.6 (6.0 to 19.3) | 27.2 (18.1 to 36.3) | 38.6 (28.5 to 48.8) |
| Week 4 | 20.7 (12.4 to 28.9) | 31.5 (21.8 to 41.1) | 50.0 (39.3 to 60.7) |
| Week 12 | 29.8 (20.0 to 39.5) | 52.6 (41.4 to 63.9) | 55.4 (44.1 to 66.7) |
The PSAAD is a daily patient reported symptom diary presented as a 15 item questionnaire that includes 11 items developed to measure symptoms of AD, along with 4 additional items for exploratory and psychometric validation purposes (Sleep \& Usual Activities Questions and Patient Global Impression of Severity \& Patient Global Impression of Change Questions). Participants answer each question about skin condition based on a 24 hour recall. Each question was evaluated on a 11-point scale ranging from 0 to 10, where higher scores indicate more impact on skin condition.The PSAAD total score is calculated as the average of the responses to each of the 11 items and ranges from 0 (none) to 10 (extreme), where higher scores indicate worse severity of AD symptoms.
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) at Week 12 | -2.0 (-2.4 to -1.6) | -2.5 (-2.9 to -2.1) | -2.7 (-3.1 to -2.3) |
The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 1.1 (0.0 to 3.2) | 6.5 (1.5 to 11.6) | 12.8 (6.0 to 19.5) |
| Week 4 | 3.1 (0.0 to 6.6) | 19.6 (11.5 to 27.7) | 38.3 (28.5 to 48.1) |
| Week 8 | 16.0 (8.6 to 23.4) | 30.8 (21.3 to 40.3) | 48.9 (38.7 to 59.1) |
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 4.4 (0.2 to 8.6) | 19.6 (11.5 to 27.7) | 25.5 (16.7 to 34.3) |
| Week 4 | 14.6 (7.5 to 21.6) | 41.3 (31.2 to 51.4) | 63.8 (54.1 to 73.5) |
| Week 8 | 33.3 (23.8 to 42.9) | 60.4 (50.4 to 70.5) | 68.5 (59.0 to 78.0) |
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 24.2 (15.4 to 33.0) | 55.4 (45.3 to 65.6) | 64.9 (55.2 to 74.5) |
| Week 4 | 51.0 (41.0 to 61.0) | 75.0 (66.2 to 83.8) | 81.9 (74.1 to 89.7) |
| Week 8 | 65.6 (55.9 to 75.2) | 85.7 (78.5 to 92.9) | 82.6 (74.9 to 90.4) |
| Week 12 | 69.1 (59.8 to 78.5) | 87.6 (80.8 to 94.5) | 87.1 (80.3 to 93.9) |
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 0 (0.0 to 4.0) | 8.7 (2.9 to 14.5) | 10.6 (4.4 to 16.9) |
| Week 4 | 2.1 (0.0 to 4.9) | 17.4 (9.6 to 25.1) | 30.9 (21.5 to 40.2) |
| Week 8 | 14.0 (6.9 to 21.0) | 29.7 (20.3 to 39.1) | 40.2 (30.2 to 50.2) |
| Week 12 | 18.1 (10.3 to 25.9) | 41.6 (31.3 to 51.8) | 49.5 (39.3 to 59.6) |
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 0 (0.0 to 4.0) | 1.1 (0.0 to 3.2) | 0 (0.0 to 3.8) |
| Week 4 | 0 (0.0 to 3.8) | 2.2 (0.0 to 5.2) | 5.3 (0.8 to 9.9) |
| Week 8 | 0 (0.0 to 3.9) | 3.3 (0.0 to 7.0) | 9.8 (3.7 to 15.9) |
| Week 12 | 2.1 (0.0 to 5.0) | 2.2 (0.0 to 5.3) | 8.6 (2.9 to 14.3) |
The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.
| Percent change | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | -27.6 (-34.0 to -21.2) | -51.5 (-57.9 to -45.1) | -54.5 (-61.0 to -48.0) |
| Week 4 | -41.7 (-48.3 to -35.1) | -66.1 (-72.7 to -59.4) | -74.3 (-81.0 to -67.5) |
| Week 8 | -57.6 (-63.4 to -51.8) | -72.6 (-78.4 to -66.8) | -77.8 (-83.7 to -71.9) |
| Week 12 | -63.7 (-69.5 to -57.9) | -77.3 (-83.1 to -71.5) | -80.6 (-86.5 to -74.8) |
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Day 2 | 1.2 (0.0 to 3.6) | 2.8 (0.0 to 6.7) | 3.9 (0.0 to 8.2) |
| Day 3 | 0 (0.0 to 4.6) | 5.1 (0.2 to 9.9) | 7.7 (1.8 to 13.6) |
| Day 4 | 4.9 (0.2 to 9.7) | 11.5 (4.4 to 18.6) | 14.3 (6.5 to 22.1) |
| Day 5 | 6.9 (1.1 to 12.8) | 12.2 (5.1 to 19.3) | 18.5 (10.1 to 27.0) |
| Day 6 | 8.8 (2.6 to 14.9) | 16.0 (8.1 to 24.0) | 21.3 (12.3 to 30.2) |
| Day 7 | 10.1 (3.5 to 16.8) | 16.0 (8.1 to 24.0) | 21.3 (12.3 to 30.2) |
| Day 8 | 4.0 (0.0 to 8.4) | 17.3 (8.8 to 25.9) | 25.0 (15.3 to 34.7) |
| Day 9 | 6.0 (0.9 to 11.1) | 16.0 (7.7 to 24.3) | 25.0 (15.5 to 34.5) |
| Day 10 | 8.3 (2.4 to 14.2) | 15.6 (7.5 to 23.7) | 28.8 (18.8 to 38.7) |
| Day 11 | 7.6 (1.8 to 13.4) | 20.8 (11.7 to 29.8) | 27.0 (16.9 to 37.1) |
| Day 12 | 10.8 (3.7 to 17.9) | 22.2 (12.6 to 31.8) | 23.6 (13.8 to 33.4) |
| Day 13 | 10.0 (3.4 to 16.6) | 26.3 (16.6 to 35.9) | 31.2 (20.8 to 41.5) |
| Day 14 | 9.5 (3.2 to 15.8) | 24.7 (15.3 to 34.1) | 32.4 (21.8 to 43.1) |
| Day 15 | 14.3 (6.8 to 21.8) | 27.7 (18.1 to 37.3) | 37.8 (27.3 to 48.3) |
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10).
| Days | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Time to First Achieve ≥4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus | 90.0 (62.0 to NA) | 70.0 (30.0 to 85.0) | 29.0 (15.0 to 61.0) |
PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10).
| Percent change | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Day 2 | -0.9 (-5.5 to 3.6) | -9.5 (-14.2 to -4.8) | -5.4 (-10.0 to -0.7) |
| Day 3 | -1.1 (-6.0 to 3.8) | -11.3 (-16.2 to -6.4) | -10.2 (-15.2 to -5.2) |
| Day 4 | -5.0 (-10.6 to 0.5) | -14.6 (-20.2 to -9.1) | -14.7 (-20.3 to -9.1) |
| Day 5 | -9.5 (-15.8 to -3.2) | -16.1 (-22.3 to -9.9) | -17.6 (-23.9 to -11.3) |
| Day 6 | -8.7 (-15.2 to -2.2) | -18.5 (-25.0 to -12.1) | -18.7 (-25.3 to -12.1) |
| Day 7 | -12.3 (-19.4 to -5.2) | -20.0 (-27.1 to -12.9) | -18.8 (-26.0 to -11.6) |
| Day 8 | -10.6 (-17.9 to -3.3) | -21.6 (-28.9 to -14.2) | -22.7 (-30.2 to -15.3) |
| Day 9 | -9.9 (-17.6 to -2.3) | -20.9 (-28.7 to -13.2) | -21.7 (-29.5 to -13.9) |
| Day 10 | -10.8 (-17.8 to -3.8) | -26.1 (-33.1 to -19.0) | -28.0 (-35.1 to -20.8) |
| Day 11 | -10.7 (-17.7 to -3.7) | -26.5 (-33.5 to -19.4) | -26.3 (-33.5 to -19.1) |
| Day 12 | -11.0 (-18.0 to -4.0) | -27.0 (-34.0 to -20.0) | -28.9 (-36.1 to -21.8) |
| Day 13 | -14.1 (-20.4 to -7.8) | -25.2 (-31.5 to -18.8) | -32.5 (-39.0 to -26.0) |
| Day 14 | -12.0 (-18.1 to -5.8) | -29.4 (-35.5 to -23.2) | -35.3 (-41.6 to -29.0) |
| Day 15 | -15.8 (-22.7 to -8.8) | -30.7 (-37.7 to -23.7) | -33.4 (-40.5 to -26.3) |
BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | -10.9 (-14.0 to -7.8) | -21.0 (-24.1 to -17.9) | -20.7 (-23.8 to -17.6) |
| Week 4 | -15.1 (-18.4 to -11.7) | -27.7 (-31.0 to -24.3) | -32.6 (-36.0 to -29.1) |
| Week 8 | -21.8 (-25.3 to -18.3) | -32.6 (-36.1 to -29.1) | -34.1 (-37.7 to -30.6) |
| Week 12 | -24.2 (-27.8 to -20.7) | -34.4 (-38.0 to -30.8) | -35.2 (-38.8 to -31.6) |
BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.
| Percent change | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | -20.6 (-26.7 to -14.5) | -40.4 (-46.5 to -34.3) | -42.2 (-48.3 to -36.1) |
| Week 4 | -29.0 (-36.3 to -21.8) | -55.4 (-62.7 to -48.1) | -66.0 (-73.4 to -58.6) |
| Week 8 | -46.0 (-52.6 to -39.3) | -65.7 (-72.4 to -59.1) | -69.5 (-76.3 to -62.8) |
| Week 12 | -53.4 (-60.1 to -46.7) | -71.4 (-78.2 to -64.7) | -72.6 (-79.3 to -65.8) |
BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Percentage of Participants Achieving Percentage BSA < 5% at Week 12 | 24.5 (15.8 to 33.2) | 38.2 (28.1 to 48.3) | 36.6 (26.8 to 46.3) |
SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 8.6 (2.9 to 14.3) | 22.6 (14.1 to 31.1) | 29.0 (19.8 to 38.3) |
| Week 4 | 24.0 (15.4 to 32.5) | 44.1 (34.0 to 54.2) | 64.1 (54.3 to 73.9) |
| Week 8 | 34.0 (24.5 to 43.6) | 65.6 (55.9 to 75.2) | 75.0 (66.2 to 83.8) |
| Week 12 | 37.6 (27.8 to 47.5) | 75.6 (66.7 to 84.4) | 73.9 (64.9 to 82.9) |
SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 0 (0.0 to 3.9) | 5.4 (0.8 to 10.0) | 7.5 (2.2 to 12.9) |
| Week 4 | 0 (0.0 to 3.8) | 11.8 (5.3 to 18.4) | 21.7 (13.3 to 30.2) |
| Week 8 | 8.5 (2.9 to 14.2) | 17.2 (9.5 to 24.9) | 33.7 (24.0 to 43.4) |
| Week 12 | 12.9 (6.1 to 19.7) | 36.7 (26.7 to 46.6) | 34.8 (25.1 to 44.5) |
SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | -12.3 (-15.4 to -9.2) | -24.6 (-27.7 to -21.6) | -25.8 (-28.9 to -22.7) |
| Week 4 | -20.2 (-23.3 to -17.0) | -32.4 (-35.5 to -29.2) | -38.0 (-41.2 to -34.8) |
| Week 8 | -26.6 (-30.0 to -23.2) | -37.3 (-40.7 to -33.9) | -41.5 (-45.0 to -38.0) |
| Week 12 | -30.2 (-33.9 to -26.4) | -40.9 (-44.7 to -37.2) | -42.9 (-46.7 to -39.1) |
SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.
| Percent change | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | -18.7 (-23.1 to -14.2) | -36.1 (-40.6 to -31.7) | -38.7 (-43.2 to -34.2) |
| Week 4 | -30.0 (-34.5 to -25.5) | -47.4 (-52.0 to -42.9) | -56.9 (-61.6 to -52.3) |
| Week 8 | -39.9 (-44.9 to -34.8) | -54.0 (-59.0 to -48.9) | -62.0 (-67.2 to -56.9) |
| Week 12 | -44.4 (-50.1 to -38.8) | -59.2 (-64.9 to -53.6) | -64.3 (-70.1 to -58.6) |
SCORAD is a validated scoring index for AD, which combines extent (A, 0-100), severity (B, 0-18), and subjective symptoms (C, 0-20) based on pruritus and sleep loss, each scored (0-10). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (ie, itch and sleep loss) are each scored by the participant using a VAS where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleep loss). The value for each should reflect the average on a 10 point scale for the last 3 days/nights. Changes from baseline in SCORAD subjective assessments of itch were not evaluated. Only changes from baseline in SCORAD subjective assessments of sleep loss are presented below.
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | -0.9 (-1.4 to -0.4) | -2.1 (-2.6 to -1.6) | -2.6 (-3.1 to -2.1) |
| Week 4 | -1.8 (-2.3 to -1.3) | -2.9 (-3.3 to -2.4) | -3.4 (-3.9 to -2.9) |
| Week 8 | -2.2 (-2.7 to -1.7) | -3.3 (-3.8 to -2.9) | -3.7 (-4.2 to -3.2) |
| Week 12 | -2.7 (-3.2 to -2.2) | -3.5 (-3.9 to -3.0) | -3.9 (-4.4 to -3.4) |
SCORAD is a validated scoring index for AD, which combines extent (A, 0-100), severity (B, 0-18), and subjective symptoms (C, 0-20) based on pruritus and sleep loss, each scored (0-10). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (ie, itch and sleep loss) are each scored by the participant using a VAS where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleep loss). The value for each should reflect the average on a 10 point scale for the last 3 days/nights. Changes from baseline in SCORAD subjective assessments of itch were not evaluated. Only changes from baseline in SCORAD subjective assessments of sleep loss are presented below.
| Percent change | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 2.6 (-101.2 to 106.3) | 65.1 (-39.2 to 169.4) | -36.5 (-140.7 to 67.8) |
| Week 4 | -20.0 (-35.2 to -4.9) | -35.2 (-50.7 to -19.8) | -53.4 (-69.1 to -37.8) |
| Week 8 | -24.7 (-60.1 to 10.8) | -44.2 (-79.9 to -8.5) | -30.6 (-66.7 to 5.5) |
| Week 12 | -39.5 (-77.7 to -1.3) | -49.8 (-88.3 to -11.3) | -35.2 (-74.1 to 3.7) |
| Days | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Number of Days When a Corticosteroid Not Used up to Day 88 | 6.8 (2.0 to 11.6) | 10.9 (6.2 to 15.5) | 15.1 (10.2 to 19.9) |
The DLQI is a general dermatology questionnaire that consists of 10 items to assess participant-reported health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment).The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 3-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality. Participants who withdrew from the study were counted as non-responder.
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | -4.2 (-5.1 to -3.3) | -6.1 (-7.1 to -5.2) | -6.3 (-7.2 to -5.3) |
| Week 4 | -5.4 (-6.3 to -4.5) | -7.3 (-8.2 to -6.4) | -7.6 (-8.6 to -6.7) |
| Week 8 | -6.1 (-7.0 to -5.1) | -8.1 (-9.1 to -7.1) | -8.2 (-9.2 to -7.2) |
| Week 12 | -6.3 (-7.4 to -5.3) | -8.6 (-9.6 to -7.5) | -8.7 (-9.7 to -7.6) |
The DLQI is a general dermatology questionnaire that consists of 10 items to assess participant-reported health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment).The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 3-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality. Participants who withdrew from the study were counted as non-responder.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 61.5 (51.5 to 71.5) | 73.6 (64.6 to 82.7) | 71.3 (62.1 to 80.4) |
| Week 4 | 73.7 (64.8 to 82.5) | 82.4 (74.6 to 90.2) | 73.4 (64.5 to 82.3) |
| Week 8 | 71.0 (61.7 to 80.2) | 85.9 (78.8 to 93.0) | 79.6 (71.4 to 87.8) |
| Week 12 | 67.7 (58.2 to 77.2) | 80.9 (72.7 to 89.1) | 78.5 (70.1 to 86.8) |
The HADS is a 14-item patient reported outcome (PRO) measure used to detect states of anxiety and depression over the past week. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | -1.2 (-1.7 to -0.7) | -1.6 (-2.1 to -1.1) | -1.3 (-1.8 to -0.8) |
| Week 4 | -1.5 (-2.1 to -1.0) | -1.6 (-2.2 to -1.1) | -1.9 (-2.5 to -1.3) |
| Week 8 | -1.7 (-2.3 to -1.1) | -2.1 (-2.7 to -1.5) | -2.2 (-2.8 to -1.5) |
| Week 12 | -2.1 (-2.7 to -1.5) | -2.0 (-2.6 to -1.4) | -2.4 (-3.0 to -1.8) |
The HADS is a 14-item patient reported outcome (PRO) measure used to detect states of anxiety and depression over the past week. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | -0.8 (-1.3 to -0.3) | -1.2 (-1.7 to -0.8) | -0.8 (-1.3 to -0.3) |
| Week 4 | -0.8 (-1.3 to -0.3) | -1.3 (-1.8 to -0.8) | -1.3 (-1.8 to -0.8) |
| Week 8 | -1.1 (-1.6 to -0.6) | -1.4 (-1.9 to -0.9) | -1.2 (-1.7 to -0.7) |
| Week 12 | -1.0 (-1.5 to -0.5) | -1.4 (-1.9 to -0.8) | -1.2 (-1.7 to -0.6) |
The POEM is a 7-item PRO measure used to assess the impact of AD over the past week. Each item is scored as "no days (0)", "1-2 days (1)", "3-4 days (2)", "5-6 days (3)" and "every day (4)". The score ranges from 0 to 28. The higher values represent more severe AD.
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | -3.4 (-4.7 to -2.1) | -6.9 (-8.2 to -5.6) | -8.2 (-9.5 to -6.9) |
| Week 4 | -4.8 (-6.0 to -3.6) | -9.5 (-10.7 to -8.3) | -10.6 (-11.9 to -9.4) |
| Week 8 | -5.4 (-6.7 to -4.0) | -10.0 (-11.4 to -8.7) | -10.6 (-12.0 to -9.3) |
| Week 12 | -6.9 (-8.3 to -5.6) | -11.1 (-12.5 to -9.7) | -10.9 (-12.2 to -9.5) |
The DFI is a validated 10-item measure filled out by the parent/caregiver of the patient used to assess the impact of the patient's eczema on the family. The instrument has a recall period of 7 days. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" or "not at all (0)". The score can range from 0 to 30. The higher values represent the worse impact.
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Change From Baseline in Dermatitis Family Impact (DFI) at Week 12 | -5.2 (-6.5 to -3.9) | -6.7 (-7.9 to -5.4) | -7.3 (-8.6 to -6.0) |
The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the IGA were used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | -0.4 (-0.6 to -0.3) | -0.7 (-0.9 to -0.6) | -1.0 (-1.1 to -0.8) |
| Week 4 | -0.7 (-0.8 to -0.5) | -0.9 (-1.1 to -0.8) | -1.2 (-1.4 to -1.1) |
| Week 8 | -0.8 (-1.0 to -0.6) | -1.2 (-1.3 to -1.0) | -1.4 (-1.6 to -1.2) |
| Week 12 | -0.9 (-1.1 to -0.7) | -1.4 (-1.6 to -1.2) | -1.6 (-1.8 to -1.4) |
The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the IGA were used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.
| Percentage of participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 1.1 (0.0 to 3.2) | 5.4 (0.8 to 10.1) | 5.3 (0.8 to 9.9) |
| Week 4 | 4.2 (0.2 to 8.2) | 14.1 (7.0 to 21.2) | 20.2 (12.1 to 28.3) |
| Week 8 | 6.4 (1.4 to 11.3) | 22.6 (14.1 to 31.1) | 26.9 (17.9 to 35.9) |
| Week 12 | 10.6 (4.4 to 16.9) | 30.0 (20.5 to 39.5) | 36.6 (26.8 to 46.3) |
The EQ-5D is a validated, standardized, generic instrument that is the most widely used preference based health related quality of life questionnaire in cost effectiveness and health technologies assessment. The EQ-5D-Y is a version of the instrument specifically developed and validated for use by youths aged 12 through 17 years. Components assess level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. Score scale for each domain ranges from 1 (minimum) to 3 (maximum), with higher scores indicating worse health condition. In addition, respondents use a vertical, graduated Visual Analogue Scale (VAS) to rate their own health between 0 (the worst) and 100 (the best health state he/she can imagine).
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Week 2 | 7.140 (3.787 to 10.492) | 11.241 (7.882 to 14.601) | 12.141 (8.763 to 15.520) |
| Week 4 | 8.784 (5.625 to 11.943) | 13.222 (10.020 to 16.423) | 14.677 (11.438 to 17.917) |
| Week 8 | 8.415 (4.888 to 11.941) | 14.502 (10.977 to 18.028) | 14.653 (11.076 to 18.231) |
| Week 12 | 9.944 (6.373 to 13.515) | 14.226 (10.624 to 17.828) | 15.756 (12.153 to 19.360) |
The Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F) is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (none of the time) to 4 (all of the time). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score), with higher scores representing better overall health status (less fatigue). Changes from baseline at Week 12 are presented below. Changes from baseline at other scheduled time points were not evaluated.
| Units on a scale | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Change From Baseline in Pediatric Functional Assessment of Chronic Illness Therapy Fatigue Scale (Peds-FACIT-F) at Week 12 | 2.5 (1.1 to 3.9) | 4.5 (3.0 to 5.9) | 4.3 (2.9 to 5.7) |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.
| Participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| All-causality TEAEs | 50 | 54 | 59 |
| Treatment-related TEAEs | 16 | 20 | 31 |
A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.
| Participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| All-causality SAEs | 2 | 0 | 1 |
| Treatment-related SAEs | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.
| Participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| All-causality TEAEs | 2 | 1 | 2 |
| Treatment-related TEAEs | 0 | 0 | 2 |
Laboratory tests included hematology (including coagulation panel), clinical chemistry, lipid profile panel, and routine urinalysis. LLN is lower limit of normal. ULN is upper limit of normal.
| Participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Hemoglobin (g/dL) <0.8*LLN | 0 | 0 | 0 |
| Hematocrit (%) <0.8*LLN | 0 | 0 | 0 |
| Erythrocytes (10^6/mm^3) <0.8*LLN | 0 | 0 | 0 |
| Reticulocytes (10^3/mm^3) <0.5*LLN | 0 | 0 | 0 |
| Reticulocytes (10^3/mm^3) >1.5*ULN | 0 | 0 | 0 |
| Ery. Mean Corpuscular Volume (10^-15L) <0.9*LLN | 1 | 1 | 0 |
| Ery. Mean Corpuscular Volume (10^-15L) >1.1*ULN | 0 | 0 | 0 |
| Ery. Mean Corpuscular Hemoglobin (pg/cell) <0.9*LLN | 1 | 1 | 0 |
| Ery. Mean Corpuscular Hemoglobin (pg/cell) >1.1*ULN | 0 | 0 | 0 |
| Ery. Mean Corpuscular HGB Concentration (g/dL) <0.9*LLN | 0 | 0 | 0 |
| Ery. Mean Corpuscular HGB Concentration (g/dL) >1.1*ULN | 0 | 0 | 0 |
| Platelets (10^3/mm^3) <0.5*LLN | 1 | 0 | 0 |
| Platelets (10^3/mm^3) >1.75*ULN | 0 | 0 | 0 |
| Reticulocytes/Erythrocytes (%) <0.5*LLN | 0 | 0 | 0 |
| Reticulocytes/Erythrocytes (%) >1.5*ULN | 0 | 0 | 1 |
| Leukocytes (10^3/mm^3) <0.6*LLN | 0 | 0 | 0 |
| Leukocytes (10^3/mm^3) >1.5*ULN | 1 | 0 | 0 |
| Lymphocytes (10^3/mm^3) <0.8*LLN | 0 | 0 | 1 |
| Lymphocytes (10^3/mm^3) >1.2*ULN | 0 | 0 | 1 |
| Lymphocytes/Leukocytes (%) <0.8*LLN | 6 | 4 | 6 |
| Lymphocytes/Leukocytes (%) >1.2*ULN | 1 | 1 | 4 |
| Neutrophils (10^3/mm^3) <0.8*LLN | 1 | 2 | 1 |
| Neutrophils (10^3/mm^3) >1.2*ULN | 6 | 5 | 3 |
| Neutrophils/Leukocytes (%) <0.8*LLN | 5 | 3 | 7 |
| Neutrophils/Leukocytes (%) >1.2*ULN | 0 | 0 | 0 |
| Basophils (10^3/mm^3) >1.2*ULN | 3 | 0 | 0 |
| Basophils/Leukocytes (%) >1.2*ULN | 35 | 24 | 27 |
| Eosinophils (10^3/mm^3) >1.2*ULN | 63 | 55 | 39 |
| Eosinophils/Leukocytes (%) >1.2*ULN | 61 | 62 | 47 |
| Monocytes (10^3/mm^3) >1.2*ULN | 1 | 0 | 0 |
| Monocytes/Leukocytes (%) >1.2*ULN | 7 | 11 | 6 |
| Activated Partial Thromboplastin Time (sec) >1.1*ULN | 2 | 4 | 4 |
| Prothrombin Time (sec) >1.1*ULN | 4 | 6 | 8 |
| Prothrombin Intl.Normalized Ratio >1.1*ULN | 0 | 0 | 0 |
| Bilirubin (mg/dL) >1.5*ULN | 1 | 4 | 0 |
| Direct Bilirubin (mg/dL) >1.5*ULN | 0 | 0 | 0 |
| Indirect Bilirubin (mg/dL) >1.5*ULN | 1 | 2 | 0 |
| Aspartate Aminotransferase (U/L) >3.0*ULN | 1 | 1 | 3 |
| Alanine Aminotransferase (U/L) >3.0*ULN | 0 | 3 | 1 |
| Gamma Glutamyl Transferase (U/L) >3.0*ULN | 1 | 0 | 0 |
| Lactate Dehydrogenase (U/L) >3.0*ULN | 0 | 1 | 2 |
| Alkaline Phosphatase (U/L) >3.0*ULN | 0 | 0 | 1 |
| Protein (g/dL) <0.8*LLN | 0 | 0 | 0 |
| Protein (g/dL) >1.2*ULN | 0 | 0 | 1 |
| Albumin (g/dL) <0.8*LLN | 0 | 0 | 0 |
| Albumin (g/dL) >1.2*ULN | 0 | 0 | 3 |
| Urea Nitrogen (mg/dL) >1.3*ULN | 0 | 0 | 0 |
| Creatinine (mg/dL) >1.3*ULN | 3 | 2 | 0 |
| Urate (mg/dL) >1.2*ULN | 2 | 4 | 1 |
| LDL Cholesterol (mg/dL) >1.2*ULN | 2 | 2 | 3 |
| Triglycerides (mg/dL) >1.3*ULN | 17 | 11 | 13 |
| Sodium (mEq/L) <0.95*LLN | 0 | 0 | 0 |
| Sodium (mEq/L) >1.05*ULN | 0 | 0 | 0 |
| Potassium (mEq/L) <0.9*LLN | 0 | 0 | 0 |
| Potassium (mEq/L) >1.1*ULN | 1 | 0 | 0 |
| Chloride (mEq/L) <0.9*LLN | 0 | 0 | 0 |
| Chloride (mEq/L) >1.1*ULN | 0 | 0 | 0 |
| Calcium (mg/dL) <0.9*LLN | 0 | 0 | 0 |
| Calcium (mg/dL) >1.1*ULN | 0 | 0 | 0 |
| Bicarbonate (mEq/L) <0.9*LLN | 1 | 1 | 0 |
| Bicarbonate (mEq/L) >1.1*ULN | 0 | 0 | 0 |
| Glucose (mg/dL) <0.6*LLN | 0 | 0 | 0 |
| Glucose (mg/dL) >1.5*ULN | 0 | 2 | 3 |
| Creatine Kinase (U/L) >2.0*ULN | 5 | 7 | 12 |
| Cholesterol (mg/dL)>1.3*ULN | 2 | 2 | 2 |
| HDL Cholesterol (mg/dL) <0.8*LLN | 0 | 0 | 0 |
| Urine Specific Gravity (scalar) <1.003 | 0 | 0 | 0 |
| Urine Specific Gravity (scalar) >1.030 | 0 | 1 | 0 |
| Urine pH (Scalar) <4.5 | 0 | 0 | 0 |
| Urine pH (Scalar) >8 | 0 | 1 | 0 |
| Urine Glucose >=1 | 1 | 0 | 0 |
| Urine Ketones >=1 | 8 | 0 | 1 |
| Urine Protein >=1 | 4 | 5 | 0 |
| Urine Hemoglobin >=1 | 20 | 19 | 15 |
| Urine Nitrite >=1 | 0 | 1 | 0 |
| Urine Leukocyte Esterase >=1 | 7 | 14 | 17 |
| Urine Erythrocytes (/HPF) >=20 | 8 | 7 | 5 |
| Urine Leukocytes (/HPF) >=20 | 0 | 2 | 1 |
| Urine Granular Casts (/LPF) >1 | 1 | 0 | 0 |
| Urine Hyaline Casts (/LPF) >1 | 2 | 1 | 1 |
| Urine Bacteria >20 | 0 | 0 | 0 |
A 12-lead ECG was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT intervals. All scheduled ECGs were performed after the participant had rested quietly for at least 10 minutes in a supine position. Reading of ECGs were performed by a central reader who has expertise reading and interpreting ECGs in adolescents. The QTcF interval is the only prespecified ECG criteria (Marked prolongation of the QTcF interval to \>500 ms or \>60 ms change from screening ECG); data are presented below.
| Participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| QTcF Interval, Single Beat (msec) Value >500 | 0 | 0 | 0 |
| QTcF Interval, Single Beat (msec) Change From Screening >60 | 0 | 0 | 0 |
Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the seated position, after having sat calmly for at least 5 minutes.
| Participants | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Diastolic Blood Pressure Value <50mmHg | 3 | 1 | 9 |
| Diastolic Blood Pressure Increase From Baseline >= 20mmHg | 3 | 6 | 6 |
| Diastolic Blood Pressure Decrease From Baseline >= 20mmHg | 3 | 4 | 8 |
| Pulse Rate Value <40 bpm | 0 | 0 | 0 |
| Pulse Rate Value >120 bpm | 0 | 0 | 0 |
| Systolic Blood Pressure Value <90mmHg | 4 | 7 | 4 |
| Systolic Blood Pressure Increase From Baseline >=30mmHg | 2 | 1 | 2 |
| Systolic Blood Pressure Decrease From Baseline >=30mmHg | 2 | 1 | 2 |
The immunogenicity analysis was to evaluate the effect of abrocitinib on immunogenicity to a tetanus, diphtheria and pertussis combination vaccine (Tdap) vaccine in adolescent participants 12 to \<18 years of age with moderate to severe AD. Participants who completed 8 weeks of treatment with study intervention received Tdap at Week 8, and had blood samples collected for the evaluation of immunogenicity to the vaccine at Weeks 8 and 12. The fold increase was defined as the ratio (post-vaccination: pre-vaccination) of concentration values. The geometric mean fold rise (GMFR) is presented below, and was calculated by first arithmetically averaging the logarithmically transformed ratio (post-vaccination: pre-vaccination) values, and then back transformation. A 95% CI for GMFR was constructed by back transformation of the CI for the logarithmically transformed GMFRs computed using the Student's t distribution.
| Ratio | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| Diphtheria IgG Antibody | 14.00 (6.32 to 30.99) | 6.51 (2.31 to 18.34) | 34.61 (6.96 to 172.06) |
| Filamentous Hemagglutinin IgG | 15.19 (4.89 to 47.16) | 11.48 (2.65 to 49.69) | 22.77 (7.26 to 71.45) |
| Fimbriae 2/3 IgG | 1.93 (0.79 to 4.73) | 1.11 (0.85 to 1.46) | 1.47 (0.61 to 3.50) |
| Pertactin IgG | 54.03 (14.67 to 199.03) | 15.60 (5.77 to 42.14) | 60.18 (12.79 to 283.08) |
| Pertussis Toxin IgG | 6.94 (1.95 to 24.71) | 10.17 (4.71 to 21.94) | 33.16 (5.04 to 218.38) |
| Tetanus Toxoid IGG AB | 8.36 (1.62 to 43.18) | 16.26 (3.52 to 75.11) | 48.41 (9.01 to 260.09) |
| ng/mL | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|
| Plasma PF-04965842 Concentration at Week 8 | 7.882 ± 26.350 | 32.33 ± 76.506 |
| ng/mL | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|
| Plasma PF-04965842 Concentration at Week 12 | 486.6 ± 403.69 | 1271 ± 1000.4 |
Collected over 16 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/96 (0%) | 2/96 (2.1%) | 42/96 (43.8%) |
| PF-04965842 100mg QD | 0/95 (0%) | 0/95 (0%) | 40/95 (42.1%) |
| PF-04965842 200mg QD | 0/94 (0%) | 1/94 (1.1%) | 50/94 (53.2%) |
| Event | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| AnxietyPsychiatric disorders | 0/96 | 0/95 | 1/94 |
| AngioedemaSkin and subcutaneous tissue disorders | 1/96 | 0/95 | 0/94 |
| Dermatitis stopicSkin and subcutaneous tissue disorders | 1/96 | 0/95 | 0/94 |
| Event | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/96 | 7/95 | 17/94 |
| Upper respiratory tract infectionInfections and infestations | 10/96 | 9/95 | 10/94 |
| NasopharyngitisInfections and infestations | 9/96 | 8/95 | 8/94 |
| HeadacheNervous system disorders | 7/96 | 5/95 | 8/94 |
| FolliculitisInfections and infestations | 1/96 | 7/95 | 2/94 |
| DizzinessNervous system disorders | 1/96 | 0/95 | 6/94 |
| AcneSkin and subcutaneous tissue disorders | 1/96 | 3/95 | 5/94 |
| VomitingGastrointestinal disorders | 0/96 | 4/95 | 5/94 |
| PharyngitisInfections and infestations | 3/96 | 5/95 | 3/94 |
| Blood creatine phosphokinase increasedInvestigations | 0/96 | 4/95 | 4/94 |
Baseline analysis population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received.
| Age, Continuous(Years) | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD | Total |
|---|---|---|---|---|
| Mean | 14.8 ± 1.7 | 15.1 ± 1.8 | 14.7 ± 1.8 | 14.9 ± 1.7 |
| Sex: Female, Male(Participants) | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD | Total |
|---|---|---|---|---|
| Female | 52 | 50 | 38 | 140 |
| Male | 44 | 45 | 56 | 145 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 25 | 26 | 25 | 76 |
| Not Hispanic or Latino | 65 | 63 | 69 | 197 |
| Unknown or Not Reported | 6 | 6 | 0 | 12 |
| Race/Ethnicity, Customized(Participants) | Placebo | PF-04965842 100mg QD | PF-04965842 200mg QD | Total |
|---|---|---|---|---|
| White | 56 | 52 | 52 | 160 |
| Black or African American | 3 | 9 | 5 | 17 |
| Asian | 32 | 31 | 31 | 94 |
| American Indian or Alaska Native | 1 | 3 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Multiracial | 1 | 0 | 1 | 2 |
| Not reported | 2 | 0 | 0 | 2 |
Showing the first 100 of 136 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2019 to primary completion in Apr 2020, 13 months.
Results were first posted in Jun 2021, 1 year 1 month after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 13 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrocitinib